Navigation Links
Cadence Pharmaceuticals to Present at Three Investment Conferences During the Month of September 2011
Date:8/31/2011

SAN DIEGO, Aug. 31, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company will present a corporate overview at the following investment conferences:


  • Stifel Nicolaus 2011 Healthcare ConferenceDate:  

    Wednesday, September 7, 2011Time:  

    1:30pm Eastern Time (10:30am Pacific Time)Place:  

    Four Seasons Hotel in BostonSpeaker:

    Scott Byrd, SVP & Chief Commercial Officer


  • UBS Global Life Sciences ConferenceDate:  

    Tuesday, September 20, 2011Time:  

    11:30am Eastern Time (8:30am Pacific Time)Place:  

    Grand Hyatt Hotel in New York CitySpeaker:

    Ted Schroeder, President & CEO


  • JMP Securities Healthcare ConferenceDate:Wednesday, September 28, 2011Time:9:30am Eastern Time (6:30am Pacific Time)Place:

    The St. Regis Hotel in New York CitySpeaker:

    Ted Schroeder, President & CEOEach presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com on the Investor Relations page.  A replay of each webcast will available approximately three hours after the live webcast concludes and will remain available for 30 days.

    About Cadence Pharmaceuticals, Inc.Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. For more information about Cadence, visit www.cadencepharm.com.Contacts:

    William R. LaRue

    SVP, CFO

    Cadence Pharmaceuticals, Inc.

    858-436-1400
    '/>"/>


  • SOURCE Cadence Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
    2. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
    3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
    4. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
    5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
    6. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
    7. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
    8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
    9. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
    10. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
    11. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/23/2017)... March 23, 2017  The goal of the ... identify and track prescription drugs as they are distributed ... response to requirements from US FDA to better protect ... dangerous medicines. Blockchain startup Chronicled, which ... chips and blockchain technology and recently raised $6.25M, and ...
    (Date:3/23/2017)... 2017 The global reprocessed ... the top five players accounting for nearly 94% ... are Stryker Sustainability Solutions, Ethicon (Johnson & Johnson), ... VANGUARD AG. Despite the high level of consolidation, ... the prevalence of fierce competition among the key ...
    (Date:3/23/2017)... -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) today ... Phase 1 study of MM-310 in solid tumors. MM-310 ... taxane and targets the EphA2 receptor, a protein which ... tumor types, including prostate, ovarian, bladder, gastric, pancreatic and ... is an important step in evaluating MM-310,s safety and ...
    Breaking Medicine Technology:
    (Date:3/23/2017)... ... ... feature 150+ Hospital and Health System Executive Speakers including: , , ... of the United States of America: George W. Bush , Boxing Legend, Successful ... Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw Walsh , ...
    (Date:3/23/2017)... ... 23, 2017 , ... Sharon Kleyne, host of the nationally syndicated radio program, ... VoiceAmerica, recently talked on her program about how she is looking forward to World ... of an important distinction. World Water Day, Kleyne pointed out, is an occasion for ...
    (Date:3/23/2017)... ... March 23, 2017 , ... ... improve all aspects of people’s health and nutrition, announced its product Leyzene is ... , Natural Subsistence develops nutritional supplements that help people improve all aspects of ...
    (Date:3/23/2017)... ... 23, 2017 , ... Inflow IQ & Inflownomics of Raleigh, NC introduce a ... solid foundation. As experts in dangerous situations the Inflow IQ team can help ... deliver ripe, fresh, clean & refreshing knowledge systems that enhance life. , ...
    (Date:3/23/2017)... ... March 23, 2017 , ... The American Board of Quality Assurance and Utilization ... ABQAURP’s dedication to Health Care Quality and Management and Patient Safety. , It is ... the association, but also to the Health Care Quality and Patient Safety movements. Diplomates ...
    Breaking Medicine News(10 mins):